VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 464 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2014. The put-call ratio across all filers is 1.12 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $6,000 | 0.0% | 256 | -16.3% | 0.00% | 0.0% |
| Q2 2016 | $6,000 | -25.0% | 306 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $8,000 | -80.5% | 306 | -24.6% | 0.00% | -80.0% |
| Q4 2015 | $41,000 | -49.4% | 406 | -10.4% | 0.01% | -50.0% |
| Q3 2015 | $81,000 | -9.0% | 453 | +12.4% | 0.01% | 0.0% |
| Q2 2015 | $89,000 | +17.1% | 403 | +5.8% | 0.01% | +11.1% |
| Q1 2015 | $76,000 | +90.0% | 381 | +35.6% | 0.01% | +80.0% |
| Q4 2014 | $40,000 | +8.1% | 281 | 0.0% | 0.01% | 0.0% |
| Q3 2014 | $37,000 | +5.7% | 281 | 0.0% | 0.01% | +25.0% |
| Q2 2014 | $35,000 | -5.4% | 281 | 0.0% | 0.00% | -33.3% |
| Q1 2014 | $37,000 | +12.1% | 281 | 0.0% | 0.01% | +20.0% |
| Q4 2013 | $33,000 | +13.8% | 281 | 0.0% | 0.01% | +25.0% |
| Q3 2013 | $29,000 | +31.8% | 281 | +9.8% | 0.00% | +33.3% |
| Q2 2013 | $22,000 | – | 256 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |